Chronic insomnia has long been treated as a problem confined to the brain — a matter of hyperarousal, racing thoughts, and disrupted circadian signaling. A new randomized, double-blind, placebo-controlled trial suggests the gut may also be part of the picture, and that changing its bacterial population can meaningfully improve sleep.
The trial, published in the Journal of Internal Medicine, found that adults with chronic insomnia who swallowed capsules containing fecal microbes from screened healthy donors slept more efficiently and woke up less during the night than those who received a placebo — with effects that persisted for months after treatment ended.
Testing a Gut-Brain Approach to Insomnia
Researchers enrolled 80 adults with chronic insomnia disorder across seven hospitals in China and randomly assigned them to receive either fecal microbiota transplant (FMT) capsules or matching placebo capsules. Before dosing began, participants in the treatment group took a short course of antibiotics to reduce their existing gut bacteria, clearing space for the donor microbes to take hold.
Each participant then swallowed 60 capsules over the initial treatment period, followed by a booster dose of 20 more capsules two weeks later. In total, one course delivered roughly 200 billion living microbes sourced from carefully screened donor stool. Neither participants nor the clinicians assessing their sleep knew who had received the active treatment.
Objective Sleep Measures Improved, Not Just Self-Reports
The results favored the treatment group on measures that are harder to explain away as a placebo effect. Objective sleep efficiency — the percentage of time in bed actually spent asleep — improved more in the FMT group than in the placebo group, and wake after sleep onset, a measure of how much time patients spent lying awake after initially falling asleep, was reduced.
Subjective sleep quality scores, based on patients' own ratings, also favored the treatment group, and the improvements were not fleeting. Patients who received the fecal microbiota capsules reported better sleep quality than the placebo group across a follow-up window spanning two to six months, suggesting the intervention produced a durable shift rather than a short-term novelty effect.
Why the Gut Might Matter for Sleep
The trial adds to a growing body of research linking the gut microbiome to sleep regulation. Gut bacteria produce and influence levels of compounds that interact with the nervous system, including short-chain fatty acids and precursors involved in serotonin and melatonin synthesis — both central to regulating the sleep-wake cycle. Disruptions to the gut's bacterial balance have separately been associated with anxiety, inflammation, and altered stress hormone signaling, all of which can interfere with sleep onset and maintenance.
Earlier, smaller studies had suggested a connection between FMT and improved sleep in specific populations, including patients recovering from long COVID with persistent sleep disturbance. This trial is among the first to test the approach in a general chronic insomnia population using a rigorous randomized, placebo-controlled design rather than an open-label or observational format.
A Long Way From Standard Care
Fecal microbiota transplantation remains a specialized procedure, most established in medicine as a treatment for recurrent Clostridioides difficile infection, where it involves careful donor screening to avoid transmitting pathogens. Applying it to a common, largely non-life-threatening condition like insomnia raises different risk-benefit questions than using it for a dangerous gut infection, and the antibiotic pretreatment used in this trial carries its own risks, including disruption of beneficial bacteria and potential contribution to antibiotic resistance if used widely.
The 80-patient sample size, while adequate to detect a treatment effect, is too small to characterize rare side effects or to say how the approach would perform across more diverse populations, including older adults or those with insomnia complicated by other psychiatric or medical conditions. Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line, guideline-recommended treatment, and this trial does not compare FMT against it directly.
What This Means for Patients
This study does not mean patients should seek out fecal transplants for insomnia outside of a research setting — the procedure used a specific, screened donor protocol and medical supervision that isn't available through insomnia clinics today. But it does offer real evidence, from a controlled trial rather than an observational study, that the gut microbiome is not just correlated with sleep quality but may causally influence it.
For the much larger group of patients whose insomnia hasn't responded well to CBT-I or medication, the finding points toward the microbiome as a legitimate new target for future treatment development — potentially through more targeted probiotic or prebiotic approaches that could sidestep the need for antibiotic pretreatment and donor stool altogether. Larger, longer follow-up trials will be needed before any gut-directed insomnia treatment could become part of routine care.
